BioSpace News Archive

Clinical Trials Support Service Market to Witness a Rise in Revenue of US$ 47.1 Billion By 2032

The global clinical trials support service market was valued at US$ 25.2 billion in 2023 and is projected to surpass US$ 47.1 billion by 2032, growing at a CAGR of 7.22% during the forecast period from 2024 to 2032.

May 9, 2024
·
7 min read
Drug Development

Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting

Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting.

May 9, 2024
·
3 min read
Business

R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease, announced the closing of its $87 million Series B financing round.

May 9, 2024
·
5 min read
Genetown

Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today hosted a Scientific Symposium at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held in Baltimore, MD.

May 9, 2024
·
4 min read
Business

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

Lumos Pharma, Inc., a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024.

May 9, 2024
·
1 min read
Biotech Beach

Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.

May 9, 2024
·
1 min read
Business

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, reported its financial results for the first quarter ended March 31, 2024.

May 9, 2024
·
9 min read
Business

TELA Bio Reports First Quarter 2024 Financial Results

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions reported financial results for the first quarter ended March 31, 2024.

May 9, 2024
·
8 min read
Business

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio, a clinical-stage cell and genome engineering company, reported financial results for the three-month period ended March 31, 2024, and provided a business update.

May 9, 2024
·
6 min read
Business

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences, Inc. announced financial results for the first quarter ended March 31, 2024, and highlighted recent pipeline and business progress.

May 9, 2024
·
10 min read